<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535469</url>
  </required_header>
  <id_info>
    <org_study_id>U01GH000517</org_study_id>
    <nct_id>NCT01535469</nct_id>
  </id_info>
  <brief_title>Operational Research for Cryptococcal Antigen Screening</brief_title>
  <acronym>ORCAS</acronym>
  <official_title>Operational Research for Cryptococcal Antigen Screening to Improve ART Survival</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Diseases Institute, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a stepped wedge randomized trial design to evaluate the implementation of
      cryptococcal antigen (CRAG) screening and preemptive anti-fungal therapy of HIV-infected
      persons entering antiretroviral therapy (ART) outpatient treatment in Uganda. Those who are
      ART eligible with a CD4≤100 cells/mcL will have a serum/plasma CRAG performed by lateral flow
      assay. Those who are CRAG-positive and asymptomatic will be treated with high dose
      fluconazole. After 6 months survival with retention-in-care will be compared between those
      who are CRAG+ and CRAG negative
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention in care</measure>
    <time_frame>6-month</time_frame>
    <description>before/after CRAG screening implementation (All persons)
CRAG positive persons treated with high-dose fluconazole as compared to 6-month survival of CRAG negative persons who are eligible for antiretroviral therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cryptococcal meningitis-free survival time</measure>
    <time_frame>6-month</time_frame>
    <description>Cryptococcal meningitis-free survival time in those who are asymptomatic CRAG positive and treated with fluconazole compared to CRAG-negative persons with CD4&lt;100 cells/mcL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Time</measure>
    <time_frame>6-month</time_frame>
    <description>Survival time among CRAG+ vs. CRAG negative persons with CD4&lt;100 cells/mcL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of CRAG screening and preemptive treatment</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from CRAG+ test to receipt of fluconazole therapy</measure>
    <time_frame>Days from CD4 testing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause discontinuation of fluconazole</measure>
    <time_frame>6-month</time_frame>
    <description>Number of participants with early discontinuation of fluconazole for any reason (e.g. non-compliance, adverse event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with symptomatic cryptococcal meningitis</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for symptomatic cryptococcal meningitis</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3049</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <condition>Cryptococcus Neoformans</condition>
  <condition>Cryptococcosis</condition>
  <arm_group>
    <arm_group_label>CrAg Screening and Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryptococcal Antigen (CrAg) Screening with preemptive antifungal treatment per World Health Organization (WHO) guidelines. Randomized Stepped Wedge design of phased implementation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks</description>
    <arm_group_label>CrAg Screening and Fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  CD4≤100 cells/mcL

          -  Cryptococcal antigen (CRAG) positive

          -  age &gt;14 years

        Exclusion Criteria:

          -  Suspected Cryptococcal meningitis

          -  Prior known history of cryptococcal meningitis

          -  currently receiving HIV antiretroviral therapy

          -  Allergy to any azole antifungal medication

          -  Persons with known serious hepatic co-morbidities, transaminitis, or clinical jaundice
             who should not receive fluconazole in the opinion of the study investigator.

          -  Current known pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B Meya, MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David R Boulware, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Radha Rajasingham, MD</last_name>
    <role>Study Director</role>
    <affiliation>Infectious Disease Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Disease Institute, Makerere University</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kampala Capital Council Authority Clinics</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.idi-makerere.com</url>
    <description>Infectious Disease Institute</description>
  </link>
  <reference>
    <citation>Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):e85-91. doi: 10.1097/QAI.0b013e31824c837e. Review.</citation>
    <PMID>22410867</PMID>
  </reference>
  <reference>
    <citation>Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, Kamya MR, Bohjanen PR, Boulware DR. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count &lt; or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010 Aug 15;51(4):448-55. doi: 10.1086/655143.</citation>
    <PMID>20597693</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cryptococcal meningitis</keyword>
  <keyword>hiv</keyword>
  <keyword>aids</keyword>
  <keyword>implementation science</keyword>
  <keyword>stepped wedge design</keyword>
  <keyword>retention-in-care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Cryptococcosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication, data to be shared upon request to the Infectious Disease Institute Research Department as per the institutional data sharing policy.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

